Skip to main content

Table 3 Treatment-related adverse events during pembrolizumab therapy

From: Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Adverse event All grades N (%) Grade ≥ 3 N (%)
Fatigue 3 (19)  
Rash, maculo-papulara 2 (13)a  
Hypothyroidisma 2 (13)a  
Anorexia 2 (13)  
Colitisa 1 (6)a 1 (6)a
Pneumonitisa 1 (6)a 1 (6)a
Dyspneaa 1 (6)a  
Arthralgiaa 1 (6)a  
Myalgiaa 1 (6)a  
Nausea 1 (6)  
Mucositis oral 1 (6)  
Dry skin 1 (6)  
Anemia 1 (6)  
Alanine aminotransferase increased 1 (6)  
Aspartate aminotransferase increased 1 (6)  
  1. aImmune-related adverse event (only one patient with maculo-papular rash and hypothyroidism had immune-related adverse event)